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The gap between Spain’s position in the economic ranking of 
nations—it is said that we are 8th—and its position in research 
in general and in biomedicine in particular is no secret in the 
country. In order to reduce this gap, huge investments will be 
required, but also imagination and a broad set of coordinated 
actions by our researchers, encompassing those at institutes, 
universities, and private companies, and the rest of society. It is 
also no secret that biotechnology in Spain has highly qualified 
personnel. The work of these scientists, and biotechnology as 
a whole, is thriving due to the increasing funding for research, 
development, and innovation provided by the Government and 
by private firms.
The same is happening in other European countries, where 
government and private funding are converging, but in Spain 
the contributions of the private sector remain comparatively 
small in terms of population and GDP. However, the effects of 
political willpower are evident, as was the case in 2005, when 
the President of the Government presented the Ingenio 2010 
plan to support research and development in Spain. This plan is 
focused in part on biomedical research, through a promotion of 
the policies of the Ministry of Health and Consumer Protection.
Research, development, and innovation have been targeted 
by our Government because of our conviction that the knowl-
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Resum. Hi ha un desfasament clar entre el lloc que l’Estat es-
panyol ocupa a Europa des del punt de vista econòmic i el lloc 
que ocupa en recerca, en general, i en biomedicina, en particu-
lar. La biomedicina serà, sense cap mena de dubte, la ciència 
principal que protagonitzarà els canvis i avenços del segle xxi. 
Per això és essencial que el resultat del coneixement arribi a la 
pràctica clínica i es converteixi en teràpies efectives. Per a 
aconseguir que aquest desfasament desaparegui, el govern 
espanyol ha elaborat una sèrie d’iniciatives que promouen el 
desenvolupament i la recerca biomèdica, i que inclouen acci-
ons conjuntes entre les institucions, les universitats, les empre-
ses i la resta de la societat. Aquestes iniciatives, agrupades 
sota el pla Ingenio 2010, promouen les polítiques del Ministeri 
de Sanitat i Consum. Juntament amb l’Institut de Salut Carles 
III i els Centres d’Investigació Biomèdica en Xarxa (CIBER), han 
permès un ràpid creixement de l’R+D a Espanya. El Consell de 
Ministres també ha aprovat una sèrie d’accions estratègiques 
amb l’objectiu que els beneficis de la recerca biomèdica arribin 
als pacients al més aviat possible. Aquestes accions transver-
sals se centren en els camps del càncer, la medicina regenera-
tiva, la nanobiotecnologia, les molècules innovadores i la Bibli-
oteca Virtual del Sistema Nacional de Salut.
Paraules clau: recerca en biomedicina · càncer · medicina 
regenerativa
Abstract. There is a clear gap between Spain’s economic 
ranking and its position among other European countries, both 
in general research and in biomedicine. Biomedicine in particu-
lar is and will be, without a doubt, the premier science in the 
21st century, initiating the most changes and leading to the 
most significant discoveries. It is therefore essential that the 
knowledge gained reaches clinical practice and is converted 
into efficient therapies. In order to reduce this gap, the Spanish 
government has set forth a series of initiatives that support bio-
medical research and development, and which encompass in-
stitutes, universities, and private companies. These initiatives, 
grouped under the Ingenio 2010 plan, promote the policies of 
the Ministry of Health and Consumer production. Together with 
the Carlos III Health Institute and the Network of Biomedical 
Research Centers (CIBER), it will allow the rapid growth of R&D 
in Spain. The Minister’s Council has also approved a series of 
strategic actions whose goal is to ensure that the benefits of 
biomedical research reach patients as quickly as possible. 
These actions are focused on cancer therapy, regenerative 
medicine, nanobiotechnology, molecular innovation, and the 
Virtual Library of the National Health System.
Keywords: research in biomedicine · cancer · regenerative 
medicine
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edge acquired will translate into added wealth as well as tech-
nological, social, and welfare benefits. We know that invest-
ment in the health industry has strong economic advantages. 
Indeed, according to experts, in Spain it could reach a ratio of 
4:10, that is, every 10€ spent, benefits assessed at 4€ are gen-
erated for society.
There are also other, indirect benefits in that a national health 
system with quality medical services, like we have here in 
Spain, provides foreigners a feeling of security and thus at-
tracts tourists. Clearly, when we consider the health system 
and medical services we refer to the health of the Spanish pop-
ulation, but we also have to think of the most competitive in-
dustry in Spain, which is tourism, and thus to keep in mind that 
in offering a high-quality health system we are ensuring the 
continued strong performance of this industry.
Figures that reflect industry growth are the number of com-
panies created in the biotechnology sector, which in 2003 was 
149 whereas in 2006 it rose to 216. According to studies car-
ried out in 2004, the value in terms of income and direct and 
indirect employment of biotechnology in Spain was 400 million 
Euro and 36,000 people employed. Assuming that growth 
continues at the current rate (around 25% for research invest-
ments and 20% for direct employment) the prediction for the 
year 2010 is 1.6% of GDP and 100,000 people employed. Bi-
omedicine in particular is and will be, without doubt, the pre-
mier science, the one that initiates the most important changes 
and leads to the most significant discoveries in this century. 
We must take advantage of this historical opportunity by mak-
ing sure that we are in the right place to do so, and by under-
taking those measures needed to bring about the necessary 
changes.
Spanish society is highly open to and prepared for techno-
logical changes and looks forward to the results of biomedical 
research. But it is of no use to society if these results remain in 
the laboratories or are confined to specialized journals; instead, 
for patients and their relatives it is essential that knowledge 
gained is converted into efficient therapy. In Spain, knowledge 
production in biotechnology accounts for 4% of the content of 
global publications, which makes our country very competitive 
in the international community. However, the application of this 
knowledge is clearly inefficient, as only 0.16% of European pat-
ents are awarded to Spain. The Government is aware of these 
figures and is engaged in attempts to boost biomedical re-
search that is application- and therefore patient-oriented. 
Nonetheless, in order to convert our country into a biomedical 
research capitol and to ensure that the results of investigation 
reach clinical practice, we will need profound reforms and new 
strategic actions.
One of the first reforms that the government must undertake 
is to equip our country with appropriate legislation to allow sci-
entific research in the biomedical field. This is to be done in a 
proper administrative context and keeping in mind respect for 
individual rights and ethical treatment. Accordingly, the Span-
ish Parliament recently approved laws on assisted human re-
production and biomedical investigation. These laws form the 
normative basis that will allow biomedical research in Spain to 
converge with that of our neighboring countries.
Currently, we are working on regulations that form the laws 
governing biomedical research. Amongst these regulations are 
Royal decrees addressing: (1) requirements for importation 
and exportation of gametes, cells, and human embryo tissue; 
(2) regulation of the employment of civil servants by private 
companies subsequent to the granting of patents or the 
achievement of research results generated in government 
centers; (3) the development and functioning of the Guarantee 
Commission for the Donation and Utilization of Cells and Hu-
man Tissue, and (4) the constitution and functioning of Ethics 
Committees in biomedical research. In addition to juridical rules 
regulating research, we need a structure to develop research 
centers and innovative projects, both of which will be financed 
with public funding.
During the past several years, the role of the Instituto de 
Salud Carlos III in furthering biomedical research in Spain has 
been crucial, but now a further step needs to be taken to trans-
form that institute into a structure that will allow us to introduce 
a new philosophy, management by targets, and thus a philoso-
phy that allows higher flexibility in management processes. 
Consequently, the Institute will become a state agency and its 
responsibilities will be leading the research activities of the Na-
tional Health System and promoting the transfer of results in 
clinical research in order to facilitate the development of their 
practical applications. Additionally, we need to finance re-
search and create policies that stimulate private companies, 
thereby uniting government and industry in the common task 
of generating wealth and well-being.
In this sense, the Ministry of Health and Consumer Protec-
tion has invested strongly in the development of basic and clin-
ical research and in projects and new buildings related directly 
to biomedicine. Increases in public funding, from 99 million Eu-
ros in 2003 to 215 million Euros in 2006, of centers such as 
CIBER (Network of Biomedical Research Centers) and the Re-
generative Medicine Center of Barcelona, under the auspices 
of the Instituto de Salud Carlos III, have allowed R&D to grow in 
a spectacular fashion. Of interest to this audience is the fact 
that of the nine divisions of CIBER, three are led by Catalan re-
searchers, and over 1000 Catalan researchers participate in 
CIBER. This indicates the extraordinary importance of re-
searchers in Catalunya to the leadership of biomedical re-
search projects throughout the country. During this past year, 
the growth of those projects has increased by 15% and in the 
2008 budget an increase of 25% in R&D in biomedical research 
was predicted, which will correspond to a total investment of 
417 million Euros.
These are figures that specifically refer to the budget of the 
Ministry of Health and Consumer Protection, but the total in-
vestment of the Government of Spain in biomedical and related 
research is much higher. For example, the Ministry of Educa-
tion and Science, during the year 2006, established many pro-
grams aimed at improving the quality of life. The funding for 
these programs was 142 million Euros. Summing the amounts 
invested in health and biotechnology by these two ministries 
and by the Ministry of Industry, we reach a total investment of 
over 2 billion Euros.
As noted above, research results must benefit society and 
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its individual citizens. This is particularly the case for biomedical 
research. Patients, their relatives, and their loved ones are not 
satisfied with knowing that many resources are devoted to re-
search activities and thus to many researchers; they want re-
sults and expect that all this knowledge and resources will 
eventually be transformed into effective therapies that heal the 
ill. This was my aim as a researcher and it remains my aim as 
Minister of Health in the Spanish Government, to advocate pa-
tient-oriented research. For this reason, the Ministers’ Council 
recently approved a series of strategic actions whose goal is to 
ensure that the benefits of biomedical research reach the pa-
tient as fast as possible. These actions, for which 75 million 
Euros have been allocated, will mobilize resources in the fol-
lowing fields: advanced therapies in regenerative medicine, 
child and adolescent psychiatry, human genetics, and rare dis-
eases and orphan drugs.
Of particular interest is regenerative medicine, which as we 
know will be the most revolutionary medical field in the 21st 
century. The Spanish Government, from the very start of its 
current term of office, has given high priority to research in re-
generative medicine and the transfer of its discoveries to the 
National Health System. Of the 21 million Euros invested, 10.5 
million are through direct funding by the government and the 
rest through joint funding. The pathologies included in the clini-
cal research program reflect the needs of patients: islet cell 
transplant for the treatment of diabetes; cell therapy in compli-
cations due to diabetes, such as diabetic foot and diabetic car-
diomyopathy; cell therapy for amyotrophic lateral sclerosis, 
multiple sclerosis; graft-versus-host disease, Crohn’s disease, 
muscular dystrophy, and spinal cord injury; the regeneration of 
skin, bone, and cartilage; and hepatic regeneration. With this 
list we start down a path that will inevitably lead to new targets, 
as research groups develop proposals with experimental and 
clinical implications that also meet the ethical and regulatory 
standards of the European Union.
The group of five actions specified in the research, develop-
ment, and innovation plan is aimed at scientific production, the 
training of researchers and medical staff, increasing the number 
of biomedical-related patents in Spain, increasing the number 
of Spanish licenses and contracts, the creation of new com-
panies (spin-offs), obtaining private funds to finance biomedi-
cal research, and of course, to improve the quality of medical 
care. These five actions are focused on: (1) cancer, with the 
goal of accelerating the transmission of scientific knowledge 
to cancer sufferers, with a total investment of 90 million Euros; 
(2) regenerative medicine, with the aim of giving continuity to 
actions already initiated in this field and to incorporate similar 
initiatives in the future, with a total investment of 22 million Eu-
ros; (3) nanobiotechnology, bioengineering, and health tech-
nology, the interaction of which is one of the most promising 
fields in research, with the intention of unifying the methods 
and concepts of engineering, biology, medicine, physics, ma-
terials science, biotechnology, etc., including experimental 
and theoretical approaches and their applications, for which 
20 million Euros is destined; (4) molecular innovation, another 
encouraging field in this century for fighting certain diseases, 
with a total of 30 million Euro invested, and (5) the Virtual Li-
brary of the National Health System, the main target of which 
is to provide all professionals in the National Health System 
access to bibliographic and documentary resources in health 
sciences.
All of these actions that form, but do not completely consti-
tute, the immediate future of biomedical research in Spain, are 
only the first steps in achieving parity with our neighboring 
countries. Moreover, they also send a message of determined 
commitment, evidenced by the specific steps undertaken by 
the Government, to society, researchers and professionals in 
the National Health System, and especially to patients, who, 
after all, are the main motivation for our work.
Finally, I would like to mention and honor Pascual Maragall, 
for the strength with which he has faced the diagnosis of Alzhe-
imer’s disease. I do so both personally and as head of the Min-
istry of Health and Consumer Protection. The fight against 
Alzheimer’s disease is one of the main priorities of the Spanish 
Government, as expressed in its laws aimed at improving the 
situation of patients and their care-takers; but it is also a battle 
that includes other fronts, such as early diagnosis, productive 
investigations, and the search for new and more effective treat-
ments. In 2006, the CIBER division of neurodegenerative dis-
eases was established, comprising 48 research groups and a 
funding commitment of nearly 6 million Euros. I would also like 
to emphasize the research units of the Alzheimer Project of the 
Reina Sofia Foundation, within the Institut Carlos III, with its ties 
to the Ministry of Health and Consumer Protection. During the 
past few years, 33 research projects focused on Alzheimer’s 
disease have been financed. These figures are meant to reas-
sure the sufferers of this disease and their relatives that the de-
termined will of the Government in this matter goes much fur-
ther than just words.
Society, its citizens and its patients have placed their hopes 
in our work. Our obligation is not to disappoint them, to not 
disappoint you.
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